Xeris Biopharma Holdings, Inc. (XERS) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2025. Xeris Biopharma is a commercial-stage biopharmaceutical company focused on therapies for chronic endocrine and neurological diseases. Its primary commercial products are Recorlev (Cushing's syndrome), Gvoke (severe hypoglycemia), and Keveyis (Primary Periodic Paralysis). The company is also developing XP-8121, a once-weekly subcutaneous levothyroxine.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Total Revenue | $71,539 | $131,658 | $88,703 |
| Net Loss | $(1,928) | $(11,148) | $(33,985) |
| Operating Income (Loss) | $4,482 | $1,392 | $(22,432) |
| Cash and Cash Equivalents | $59,285 | $59,285 | $71,621 (Dec 31, 2024) |
| Total Debt (Net) | $218,626 | $218,626 | $232,108 (Dec 31, 2024) |
| Stockholders' Equity (Deficit) | $(19,304) | $(19,304) | $(29,615) (Dec 31, 2024) |
Revenue Breakdown (YTD 2025): Recorlev ($56.97M), Gvoke ($44.31M), Keveyis ($22.91M).
Cash Flow (YTD 2025): Net cash used in operating activities was $9.8M, compared to $30.7M in the prior year period. Net cash used in financing activities was $2.2M.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 48.4% year-over-year for the six months ended June 30, 2025. This was driven primarily by a 138.0% increase in Recorlev revenue and a 21.0% increase in Gvoke revenue.
- Profitability Improvement: The company achieved operating income of $4.5M in Q2 2025, a significant turnaround from an operating loss of $8.2M in Q2 2024. The net loss narrowed significantly to $1.9M in Q2 2025 from $15.0M in Q2 2024.
- Debt Reduction: Total debt decreased from $232.1M at year-end 2024 to $218.6M as of June 30, 2025. This reduction was largely due to the conversion of $15.2M of 2025 Convertible Senior Notes into common stock during March and April 2025.
- Expense Increases: Selling, general, and administrative (SG&A) expenses increased 12.8% YTD, primarily due to investments in the Recorlev commercial organization. R&D expenses increased 16.4% YTD.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes current cash resources are sufficient to sustain operations for at least the next 12 months. However, the company expects to continue incurring net losses and may require additional equity or debt financing in the future.
- Debt Maturity: The 2029 Loans (Term Loan) mature on March 5, 2029, but could mature earlier on January 15, 2028, if the 2028 Convertible Notes are not redeemed or extended. The 2028 Convertible Notes mature in September 2028.
- Risks: Key risks include the ability to successfully commercialize products, reliance on single-source suppliers, potential inability to raise capital on acceptable terms, and macroeconomic factors such as interest rates and geopolitical instability.
- Pipeline: The company is working with the FDA to plan and initiate a Phase 3 clinical trial for XP-8121 (once-weekly levothyroxine).
Investor Verification Checklist
- Debt Covenants and Maturities: Verify the specific conditions under which the 2029 Loans could mature early in January 2028 and the company's plan to refinance or repay the 2028 Convertible Notes.
- Recorlev Growth Sustainability: Assess whether the 138% year-over-year growth in Recorlev revenue is sustainable given the small market size for Cushing's syndrome and potential pricing pressures.
- Cash Burn Rate: Monitor the trend in operating cash flow usage to ensure the "12-month runway" assertion remains valid as commercialization costs for Recorlev continue to rise.
- Inventory Levels: Review the increase in inventory (from $48.2M to $67.3M) and the associated reserves ($10.1M) to ensure no significant obsolescence risks, particularly for Gvoke components.
- Dilution Impact: Evaluate the impact of the recent conversion of convertible notes and the large number of anti-dilutive securities (warrants, options, RSUs) on future earnings per share.